|
1
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
3
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39:10104283177146262017. View Article : Google Scholar
|
|
4
|
Sunil C and Xu B: An insight into the
health-promoting effects of taxifolin (dihydroquercetin).
Phytochemistry. 166:1120662019. View Article : Google Scholar
|
|
5
|
Li J, Hu L, Zhou T, Gong X, Jiang R and Li
H, Kuang G, Wan J and Li H: Taxifolin inhibits breast cancer cells
proliferation, migration and invasion by promoting mesenchymal to
epithelial transition via β-catenin signaling. Life Sci.
232:1166172019. View Article : Google Scholar
|
|
6
|
Razak S, Afsar T, Ullah A, Almajwal A,
Alkholief M, Alshamsan A and Jahan S: Taxifolin, a natural
flavonoid interacts with cell cycle regulators causes cell cycle
arrest and causes tumor regression by activating Wnt/β-catenin
signaling pathway. BMC Cancer. 18:10432018. View Article : Google Scholar
|
|
7
|
Wang R, Zhu X, Wang Q, Li X, Wang E, Zhao
Q, Wang Q and Cao H: The anti-tumor effect of taxifolin on lung
cancer via suppressing stemness and epithelial-mesenchymal
transition in vitro and oncogenesis in nude mice. Ann Transl Med.
8:5902020. View Article : Google Scholar
|
|
8
|
Chen X, Gu N, Xue C and Li BR: Plant
flavonoid taxifolin inhibits the growth, migration and invasion of
human osteosarcoma cells. Mol Med Rep. 17:3239–3245. 2018.
|
|
9
|
Percie du Sert N, Hurst V, Ahluwalia A,
Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl
U, et al: The ARRIVE guidelines 2.0: Updated guidelines for
reporting animal research. PLoS Biol. 18:e30004102020. View Article : Google Scholar
|
|
10
|
National Research Council (US): Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the Care and Use of Laboratory Animals. National
Academies Press; Washington, DC: 2011
|
|
11
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar
|
|
12
|
Wu H, Wang W, Tong S and Wu C:
Nucleostemin regulates proliferation and migration of gastric
cancer and correlates with its malignancy. Int J Clin Exp Med.
8:17634–17643. 2015.
|
|
13
|
Scheau C, Badarau IA, Costache R, Caruntu
C, Mihai GL, Didilescu AC, Constantin C and Neagu M: The role of
matrix metalloproteinases in the epithelial-mesenchymal transition
of hepatocellular carcinoma. Anal Cell Pathol (Amst).
2019:94239072019.
|
|
14
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar
|
|
15
|
Yang HL, Thiyagarajan V, Shen PC, Mathew
DC, Lin KY, Liao JW and Hseu YC: Anti-EMT properties of CoQ0
attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through
ROS-mediated apoptosis. J Exp Clin Cancer Res. 38:1862019.
View Article : Google Scholar
|
|
16
|
Wu YJ, Lin SH, Din ZH, Su JH and Liu CI:
Sinulariolide inhibits gastric cancer cell migration and invasion
through downregulation of the EMT process and suppression of
FAK/PI3K/AKT/mTOR and MAPKs signaling pathways. Mar Drugs.
17:6682019. View Article : Google Scholar
|
|
17
|
Kamenickova A and Dvorak Z: Effects of
flavored mineral waters on AhR-CYP1A1 signaling pathway in primary
human hepatocytes and in human hepatic and intestinal cancer cells.
Food Chem Toxicol. 50:1933–1939. 2012. View Article : Google Scholar
|
|
18
|
Haarmann-Stemmann T, Abel J, Fritsche E
and Krutmann J: The AhR-Nrf2 pathway in keratinocytes: On the road
to chemoprevention? J Invest Dermatol. 132:7–9. 2012. View Article : Google Scholar
|
|
19
|
Maayah ZH, Ghebeh H, Alhaider AA, El-Kadi
AO, Soshilov AA, Denison MS, Ansari MA and Korashy HM: Metformin
inhibits 7,12-dimethylbenz[a]anthracene-induced breast
carcinogenesis and adduct formation in human breast cells by
inhibiting the cytochrome P4501A1/aryl hydrocarbon receptor
signaling pathway. Toxicol Appl Pharmacol. 284:217–226. 2015.
View Article : Google Scholar
|
|
20
|
Vondracek J, Umannova L and Machala M:
Interactions of the aryl hydrocarbon receptor with inflammatory
mediators: Beyond CYP1A regulation. Curr Drug Metab. 12:89–103.
2011. View Article : Google Scholar
|
|
21
|
Al-Dhfyan A, Alhoshani A and Korashy HM:
Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates
breast cancer stem cells expansion through PTEN inhibition and
beta-Catenin and Akt activation. Mol Cancer. 16:142017. View Article : Google Scholar
|
|
22
|
Yin J, Sheng B, Pu A, Han B, Yang K, Wang
Q, Sun L and Yang H: Keratinocyte growth factor regulation of aryl
hydrocarbon receptor activation in colorectal cancer cells. Dig Dis
Sci. 61:444–452. 2016. View Article : Google Scholar
|
|
23
|
Yin XF, Chen J, Mao W, Wang YH and Chen
MH: Downregulation of aryl hydrocarbon receptor expression
decreases gastric cancer cell growth and invasion. Oncol Rep.
30:364–370. 2013. View Article : Google Scholar
|
|
24
|
Haque MW and Pattanayak SP: Taxifolin
inhibits 7,12-dimethylbenz(a)anthracene-induced breast
carcinogenesis by regulating AhR/CYP1A1 signaling pathway.
Pharmacogn Mag. 13(Suppl 4): S749–S755. 2018.
|
